About Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
Headquarters251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Founded2018
StatusActive
Patents1 patent
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
Reviews
No reviews yet. Worked with Assertio Therapeutics, Inc.? Be the first to share your experience.
Legal information
| Legal name | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20View on GLEIF ↗ |
| Registered address | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| Status | Active |
Sources: GLEIF · updated Oct. 16, 2026
Contact & links
Location
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
Is this your company?
Claim this page for free to add your logo, products, photos and jobs, and to answer reviews.
Claim this pageJoin Heelky to connect, hire and grow
Create a free account to message people, apply to jobs and post missions.
Join now — it's free